Page 144 - 4PDF Alin Dexametasona

ESTEROIDES EN NEUMONÍA SEVERA POR SARS-COV-2

Bibliografía

1. Stockman LJ, Bellamy R, Garner P (2006) SARS: Systematic Re-
view of Treatment Effects. PLOS Medicine 3(9): e343. https://doi.
org/10.1371/journal.pmed.0030343
2. Zhikang Ye MPharm, Ying Wang MPharm, Luis Enrique Colun-
ga-Lozano MD MSc, Manya Prasad MD MBBS, Wimonchat Tan-
gamornsuksan PharmD PhD, Bram Rochwerg MD MSc, Liang Yao
MSc, Shahrzad Motaghi MSc, Rachel J. Couban MA MISt, Maryam
Ghadimi PharmD BCPS, Malgorzata M. Bala MD PhD, Huda Go-
maa MSc,Fang Fang MD, Yingqi Xiao MN, Gordon H. Guyatt MD
MSc. Efficacy and safety of corticosteroids in COVID-19 based on
evidence for COVID-19, other coronavirus infections, influenza,
community-acquired pneumonia and acute respiratory distress sy-
ndrome: a systematic review and meta-analysis. CMAJ 2020. doi:
10.1503/cmaj.200645; early-released May 14, 2020
3. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute
Respiratory Distress Syndrome and Death in Patients With Coro-
navirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern
Med. 2020;180(7):934–943. doi:10.1001/jamainternmed.2020.0994
4. Effect of dexamethasone in hospitalized patients with COVID-19—
preliminary report. 22 Jun 2020 (preprint). https://www.medrxiv.
org/content/10.1101/2020.06.22.20137273v1.

143